Braftovi®plus cetuximab is the first U.S. Food and Drug Administration (FDA)-approved targeted treatment regimen for adults with previously treated metastatic CRC with a BRAF^V600E mutation

On April 8, the FDA approved Braftovi (encorafenib) in combination with cetuximab for the treatment of adults with BRAF^V600E-mutant metastatic colorectal cancer (CRC) who have received prior therapy. This type of mutation-driven CRC is typically associated with a poor prognosis. Before the approval of Braftovi plus cetuximab, there were no targeted treatment regimens specifically approved for these patients.

Given the high unmet need, Pfizer was committed to bringing this critical treatment option to adults with previously treated BRAF^V600E-mutant metastatic CRC, despite the widespread COVID-19 pandemic that was surging across the nation. The approval happened amid many stay-at-home restrictions, making this Pfizer’s first-ever virtual product launch in the U.S. Challenges aside, the team quickly pivoted in a five-week timeframe to ensure patients and health care providers were aware of this much-needed regimen.

As the first regulatory approval in the U.S. following Pfizer’s acquisition of Array BioPharma Inc., the Company is proud to bring this regimen to market without delay. It is a testament to our commitment to developing targeted medicines for difficult-to-treat, mutation-driven cancers.

Looking to 2021 and beyond, Pfizer remains steadfast in its commitment to helping certain patients with BRAF-mutant metastatic CRC and is excited to continue investigating this treatment regimen. Pfizer’s purpose remains unchanged – Breakthroughs that change patients’ lives. Looking ahead, Pfizer hopes to positively impact the lives of more people battling this devastating type of cancer.